Project phase 01.07.2002 - 30.06.2005

Ca.-No 98

Phenotypic reversal in multidrug resistant cancer cells

Israeli Partner: M. Liscovitch, Weizmann Institute of Science
German Partner: D. Keppler, DKFZ

Ca.-No 99

Targeting the adenosine A3 receptor for the treatment and prevention of colon carcinoma: molecular mechanisms and preclinical evaluation

Israeli Partner: (P. Fishman, Tel Aviv University)
German Partner: R. Koesters (div. M. v. Knebel Doeberitz), DKFZ

Publications

2003 - Oncogene, 22 (25): p. 3888-900
Burgermeister, E.; Tencer, L.; Liscovitch, M.
2005 - Oncogene, 24 (8): p. 1338-47
Ravid, D.; Maor, S.; Werner, H.; Liscovitch, M.
2008 - Anticancer Res, 28 (2): p. 895-906

Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance

Tencer, L.; Burgermeister, E.; Ebert, M. P.; Liscovitch, M.

Ca.-No 100

The CD95 (APO-1/Fas) death system in tumor progression

Israeli Partner: G. Berke, Weizmann Institute of Science
German Partner: P. Krammer, DKFZ

Publications

No publications available.

Ca.-No 101

Involvement of c-Abl in HPV-induced carcinogenesis

Israeli Partner: Y. Haupt, Hebrew University
German Partner: F. Roesl, DKFZ

Publications

2003 - Cancer Lett, 195 (1): p. 67-72

Connexin 37 gene is not mutated in lung carcinomas 3LL and CMT

Berke, G.; Krutovskikh, V.; Yamasaki, H.
2002 - Nat Rev Cancer, 2 (4): p. 277-88
Igney, F. H.; Krammer, P. H.
2007 - Immunology, 120 (4): p. 502-11
Peshes-Yaloz, N.; Rosen, D.; Sondel, P. M.; Krammer, P. H.; Berke, G.
2005 - Int J Cancer, 113 (1): p. 78-87
Igney, F. H.; Behrens, C. K.; Krammer, P. H.
2000 - Eur J Immunol, 30 (3): p. 725-31
Igney, F. H.; Behrens, C. K.; Krammer, P. H.
2001 - J Immunol, 166 (5): p. 3240-7

CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice

Behrens, C. K.; Igney, F. H.; Arnold, B.; Moller, P.; Krammer, P. H.
2003 - Eur J Immunol, 33 (10): p. 2811-21
Igney, F. H.; Behrens, C. K.; Krammer, P. H.
2002 - J Leukoc Biol, 71 (6): p. 907-20

Immune escape of tumors: apoptosis resistance and tumor counterattack

Igney, F. H.; Krammer, P. H.
2002 - Anticancer Res, 22 (5): p. 2663-9

Tumor sensitivity to anti-cancer drugs predicted by changes in fluorescence intensity and polarization in vitro

Schiffenbauer, Y. S.; Trubniykov, E.; Zacharia, B. T.; Gerbat, S.; Rehavi, Z.; Berke, G.; Chaitchik, S.

Ca.-No 102

Tyrosine kinase VEGF receptors and neuropilins and the role of their VEGF and semaphoring ligands in tumor development and progression

Israeli Partner: G. Neufeld, Technion
German Partner: M. Mueller, DKFZ

Publications

2012 - PLoS One, 7 (7): p. e42166
Lutzner, N.; Kalbacher, H.; Krones-Herzig, A.; Rosl, F.
2012 - PLoS One, 7 (3): p. e32590
Lutzner, N.; De-Castro Arce, J.; Rosl, F.

Ca.-No 103

Human papillomavirus type 16 in cervical cancer: the potential role of E6 natural variants in regression of progression of viral-induced disease

Israeli Partner: L. Sherman, Sackler School of Medicine
German Partner: L. Gissmann, DKFZ

Publications

No publications available.

Ca.-No 104

Functional significance of insulin signaling in skin and skin tumorigenesis

Israeli Partner: E. Wertheimer, Tel Aviv University
German Partner: D. Breitkreutz, DKFZ

Publications

2009 - Virology, 383 (1): p. 69-77
Zehbe, I.; Richard, C.; DeCarlo, C. A.; Shai, A.; Lambert, P. F.; Lichtig, H.; Tommasino, M.; Sherman, L.
2006 - Virology, 350 (1): p. 216-27
Lichtig, H.; Algrisi, M.; Botzer, L. E.; Abadi, T.; Verbitzky, Y.; Jackman, A.; Tommasino, M.; Zehbe, I.; Sherman, L.
1996 - Virus Res, 42 (1): p. 81-96

The E6 variant proteins E6I-E6IV of human papillomavirus 16: expression in cell free systems and bacteria and study of their interaction with p53

Shally, M.; Alloul, N.; Jackman, A.; Muller, M.; Gissmann, L.; Sherman, L.
2006 - Immunol Lett, 107 (1): p. 41-9
Samorski, R.; Gissmann, L.; Osen, W.
2007 - J Med Virol, 79 (11): p. 1751-60
Asadurian, Y.; Kurilin, H.; Lichtig, H.; Jackman, A.; Gonen, P.; Tommasino, M.; Zehbe, I.; Sherman, L.
2011 - Mol Cancer, 10: p. 77
Zehbe, I.; Lichtig, H.; Westerback, A.; Lambert, P. F.; Tommasino, M.; Sherman, L.
2010 - Virology, 396 (1): p. 47-58
Lichtig, H.; Gilboa, D. A.; Jackman, A.; Gonen, P.; Levav-Cohen, Y.; Haupt, Y.; Sherman, L.

Ca.-No 105

Macromolecular polymers as a novel platform for the tumor directed delivery of drugs targeting molecular processes of apoptosis and radiation

Israeli Partner: S. Lavi, Tel Aviv University
German Partner: P. Peschke (div. P. Huber), DKFZ

Publications

2006 - Mol Cell Biol, 26 (7): p. 2675-87
Sadagurski, M.; Yakar, S.; Weingarten, G.; Holzenberger, M.; Rhodes, C. J.; Breitkreutz, D.; Leroith, D.; Wertheimer, E.

Publications

2006 - Neoplasia, 8 (10): p. 788-95
Lammers, T.; Peschke, P.; Kuhnlein, R.; Subr, V.; Ulbrich, K.; Huber, P.; Hennink, W.; Storm, G.
2010 - Nanomedicine (Lond), 5 (10): p. 1501-23
Lammers, T.; Subr, V.; Ulbrich, K.; Peschke, P.; Huber, P. E.; Hennink, W. E.; Storm, G.; Kiessling, F.
2010 - Adv Drug Deliv Rev, 62 (2): p. 119-21
Lammers, T.; Ulbrich, K.
2009 - Biomaterials, 30 (20): p. 3466-75
Lammers, T.; Subr, V.; Ulbrich, K.; Peschke, P.; Huber, P. E.; Hennink, W. E.; Storm, G.
2008 - Br J Cancer, 99 (6): p. 900-10
Lammers, T.; Subr, V.; Peschke, P.; Kuhnlein, R.; Hennink, W. E.; Ulbrich, K.; Kiessling, F.; Heilmann, M.; Debus, J.; Huber, P. E.; Storm, G.
2005 - J Control Release, 110 (1): p. 103-18
Lammers, T.; Kuhnlein, R.; Kissel, M.; Subr, V.; Etrych, T.; Pola, R.; Pechar, M.; Ulbrich, K.; Storm, G.; Huber, P.; Peschke, P.
2012 - PLoS One, 7 (2): p. e32438
Shohat, M.; Ben-Meir, D.; Lavi, S.
2006 - Bioconjug Chem, 17 (1): p. 42-51
Kiessling, F.; Heilmann, M.; Lammers, T.; Ulbrich, K.; Subr, V.; Peschke, P.; Waengler, B.; Mier, W.; Schrenk, H. H.; Bock, M.; Schad, L.; Semmler, W.
2007 - Crit Rev Biochem Mol Biol, 42 (6): p. 437-61
Lammers, T.; Lavi, S.
2007 - Mol Cancer, 6: p. 65
Lammers, T.; Peschke, P.; Ehemann, V.; Debus, J.; Slobodin, B.; Lavi, S.; Huber, P.
Formular

Formulardaten werden geladen ...